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Abstract
Immunisation programs are designed to reduce serious morbidity and mortality from influenza, but most evidence
supporting the effectiveness of this intervention has focused on disease in the community or in primary care settings. We
aimed to examine the effectiveness of influenza vaccination against hospitalisation with confirmed influenza. We compared
influenza vaccination status in patients hospitalised with PCR-confirmed influenza with patients hospitalised with influenza-
negative respiratory infections in an Australian sentinel surveillance system. Vaccine effectiveness was estimated from the
odds ratio of vaccination in cases and controls. We performed both simple multivariate regression and a stratified analysis
based on propensity score of vaccination. Vaccination status was ascertained in 333 of 598 patients with confirmed
influenza and 785 of 1384 test-negative patients. Overall estimated crude vaccine effectiveness was 57% (41%, 68%). After
adjusting for age, chronic comorbidities and pregnancy status, the estimated vaccine effectiveness was 37% (95% CI: 12%,
55%). In an analysis accounting for a propensity score for vaccination, the estimated vaccine effectiveness was 48.3% (95%
CI: 30.0, 61.8%). Influenza vaccination was moderately protective against hospitalisation with influenza in the 2010 and 2011
seasons.
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Introduction
Influenza vaccination is required each year because of antigenic
change in circulating influenza viruses and the short –term
immunity induced by current haemagglutinin-based vaccines.
Seasonal influenza vaccine is provided free of cost in Australia to
adults aged $65 years, Indigenous Australian adults aged $15
years, those with medical comorbidities and pregnant women [1].
Although the aim of the influenza vaccination program is to
prevent serious morbidity and mortality, most clinical trials have
been performed in the community, where influenza is mostly a
mild, self-limiting illness [2–4]. We have previously reported
evidence of effectiveness of the influenza H1N1/09-containing
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vaccines against hospitalisation with H1N1/09 influenza in the
2010 season in Australia [5]. However, vaccine effectiveness
against all strains appeared to be attenuated by vaccine failures in
a small number of patients with non-H1N1/09 influenza.
In this study, we estimate vaccine coverage in hospitalized
patients and vaccine effectiveness of the seasonal influenza vaccine
against hospitalisation with confirmed influenza in the 2010 and
2011 seasons.
Methods
Study Setting and Design
This study was based on hospital-based surveillance conducted
in sentinel hospitals in Australia. In 2010, 15 hospitals based in
capital or large regional centres were involved as previously
described [6] and this study includes data on 1169 patients
previously published based on an analysis in 2010 [5]. In 2011, the
participating hospitals were The Alfred Hospital, the Royal
Melbourne Hospital, Monash Medical Centre, Geelong Hospital
(Victoria), Royal Adelaide Hospital (SA), The Canberra Hospital
and Calvary Hospital (ACT) and the Royal Perth Hospital (WA).
Prospective active surveillance was conducted for confirmed cases
of influenza presenting for admission at each hospital. We
performed a prospective test-negative study, a study design similar
to a case control study, by also collecting data on patients who had
suspected influenza but who were negative on influenza testing
(‘‘test negative controls’’). The decision to test for suspected
influenza was left to the discretion of the clinician.
Cases and Controls
Cases were defined as hospitalised adult ($18 years) patients
with influenza A or influenza B confirmed by nucleic acid
detection using polymerase chain reaction (PCR). Controls were
defined as the next hospitalised adult patient tested for suspected
influenza but found to be negative by influenza PCR, with up to
two recruited where available. Patients were identified from testing
logs maintained by laboratories or infection control units at each
hospital.
Vaccination status. Influenza vaccination was defined as
follows.
N In 2010, receipt of the monovalent H1N1/09 vaccine or the
seasonal trivalent vaccine (containing an A/California/7/2009
(H1N1) - like strain, an A/Perth/16/2009 (H3N2) - like strain
and B/Brisbane/60/2008 - like strain) in 2010 or
N In 2011, receipt of the seasonal trivalent vaccine (containing
the same strains as in 2010).
This was determined from the hospital medical record and
patient self-report; primary care practitioners were not contacted
as this was not within the scope of our ethical approval and privacy
legislation. We included the monovalent H1N1/09 vaccine in our
definition as we wanted to estimate the effectiveness of the
vaccination policy, and in 2010, 79% of admissions with
confirmed influenza were due to H1N1/09 influenza.
Other definitions. Medical risk factors were the presence of
any chronic diseases that qualified patients for publicly funded
vaccination including cardiac disease, chronic respiratory condi-
tions, other chronic illnesses requiring regular medical follow up or
hospitalisation in the previous year, including diabetes mellitus,
chronic renal failure, chronic neurological conditions and immu-
nosuppression. We also considered other groups that qualify for
publicly funded vaccine, including age $65 years, pregnant
women and Indigenous (Aboriginal or Torres Strait Islander)
Australians $15 years of age. We did not consider obesity as
height and weight measures were poorly documented.
Statistical Tests
Vaccine effectiveness was estimated from the odds ratio (OR) of
vaccination in cases and controls as (1-OR)6100%. Four methods
were used:
1. A crude analysis based on a conditional logistic regression
stratified by site and by date of testing (in two week blocks,
calculated from the epidemiological week) [5,7].
2. Simple adjustment, based on a multivariate logistic regression
adjusted for potential confounders, including the presence of
medical risk factors and age $65 years (both included in the
model), pregnancy status and Indigenous status (which were
only included if statistically significant).
3. A propensity scored analysis, based on a model based on
clinical covariates (and potential confounders) to predict
vaccination status in control patients.
4. An imputed analysis, based on a multiple imputation
procedure to augment missing vaccine status. This was used
in combination with the propensity scored analysis (to assess
the effect of imputation); analyses 1 and 2 were performed
using non-missing data (complete set) only.
The propensity score was constructed based on clinical
covariates known at the time of vaccination status in control
patients (method D reported by Mansson [8]). All covariates were
included in this model, whether statistically associated with
vaccination or otherwise. The propensity score was calculated
using the logistic regression formula. Model calibration (which
represents the probability that a randomly selected vaccinated
patient has a higher propensity score than a randomly selected
non-vaccinated patient) was assessed using the area under the
receiver operator characteristic curve. Model fit was assessed by
examining the proportion of patients vaccinated and unvaccinated
by decile of propensity score. The adequacy of covariate balance
was assessed by the mean standardized difference across deciles of
propensity score, where a difference of .10% represents a
significant residual imbalance [9]. Vaccine effectiveness was
estimated from the odds ratio of vaccination in cases and controls,
stratifying on the decile of propensity score. A Wald test was
performed to test the null hypothesis that vaccine effectiveness did
not vary across different age groups.
Imputation of missing vaccination status was performed by a
multiple imputation procedure implemented in Stata 12. This uses
logistic models for missing status and vaccination status based on
clinical covariates as well as influenza diagnosis. Fifty datasets were
imputed and vaccine effectiveness was estimated from the odds
ratio of vaccination in cases and control after stratification on the
decile of the propensity score.
Statistical tests were performed using Stata 12 (College Station,
Texas).
Ethical Statement
Ethical approval to perform surveillance and report data was
obtained from Human Research Ethics Committees of all
participating hospitals and at the Australian National University.
Due to the use of these non-identifiable data for public health
surveillance and their non-sensitive nature, written consent was
not felt to be necessary by all research ethics committees.
Where patients were contacted to clarify details of their medical
history, the nature of the study was explained and verbal
consent was obtained, and this was documented in the medical
Influenza Vaccine Effectiveness
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record. All study procedures, including the waiver of written
consent and use of verbal consent, were approved by the
following ethics committees: Australian Capital Territory Health
Human Research Ethics Committee, Australian National
University Human Research Ethics Committee, Hunter New
England Human Research Ethics Committee, Human Research
Ethics Committee for the Northern Territory Department of
Health and Menzies School of Health Research, Cairns &
Hinterland Health Service District Ethics Committee, Mater
Health Services Human Research Ethics Committee, Royal
Brisbane and Women’s Hospital Human Research Ethics
Committee, Royal Adelaide Hospital Research Ethics Commit-
tee, Tasmania Health & Medical Human Research Ethics
Committee, Alfred Hospital Ethics Committee, Barwon Health
Human Research Ethics Committee, Melbourne Health Human
Research Ethics Committee, Southern Health Human Research
Ethics Committee, Royal Perth Hospital Human Research
Ethics Committee, Western Sydney Local Health District
Human Research Ethics Committee, Metro South Health
Service District Human Research Ethics Committee.
Results
During the 2010–2011 seasons, there were 598 admissions to
sentinel hospitals with confirmed influenza (302 admissions at
15 sites in 2010 and 296 admissions at 8 sites in 2011). Of
these, 311 patients (52%) were female and the median age was
44 years (interquartile range 27, 62 years); 132 patients (22%)
were 65 years or older at admission. There were 25 Indigenous
patients admitted. Of all patients with confirmed influenza, 436
patients (73%) were reported to have a chronic medical
condition and 33 female patients (10%) were pregnant at the
time of admission.
Vaccination status was ascertained in 333 of 598 patients (56%)
with confirmed influenza; a higher proportion of patients in 2010
had vaccination status ascertained (67%) than in 2011 (44%),
largely due to a change in policy by an ethics committee at one site
precluding patient contact. Vaccination status was ascertained in
785 of 1384 (57%) of test negative control patients (Table 1).
Vaccination Coverage
In control patients where vaccination status was ascertained,
59% of 631 patients with medical comorbidities, 82% of 282
patients aged $65 years and 47% of 70 Indigenous Australians
were vaccinated with the either the monovalent H1N1/09 and/or
the 2010 seasonal vaccine in 2010, or the 2011 seasonal trivalent
vaccine in 2011.
A propensity score for vaccination was constructed using all
available clinical variables available to the clinician at the time of
vaccination. Details of the multivariate model are listed in Table 2.
The calibration of this model was moderately good
(AUROC=0.78) and the proportion of patients vaccinated
increased with increasing propensity score (Figure 1). After
stratifying on the decile of the propensity score, covariate balance
was achieved (Table 3).
Vaccine Effectiveness
The crude odds of vaccination in adults with confirmed
influenza compared to controls was 0.43 (95% CI: 0.32, 0.59);
therefore the estimated crude vaccine effectiveness was 57% (41%,
68%). After adjusting for age ($65 years), the presence of medical
comorbidities and pregnancy status (table 4), the adjusted odds of
vaccination was 0.63 (0.45, 0.88); therefore, the estimated vaccine
effectiveness using simple multivariate regression was 37% (95%
CI: 12%, 55%). Based on an analysis stratified on the decile of the
propensity score, the estimated vaccine effectiveness was 48.3%
(95% CI: 30.0, 61.8%). Estimated vaccine effectiveness in
subgroups is depicted in Figure 2. The estimated vaccine
effectiveness in patients 50–64 years was 41% (95% CI: 22.3,
66.5%) in patients 65–80 years was 47% (95% CI: 213.6, 75.7%)
and in patients.80 years was 59.2% (227.1%, 86.9%). The Wald
test did not find evidence of an interaction between the odds of
vaccination in cases and controls across different age groups
(p = 0.96).
A lower proportion of vaccinated patients with confirmed
influenza were admitted to ICU compared to unvaccinated
patients with confirmed influenza (20/109 (18%) vs 64/224
(29%); p = 0.045). In patients .65 years, 9 of 32 (28%) vaccinated
patients were admitted to ICU compared to 5 of 20 (25%)
unvaccinated patients (p = 0.5). In patients ,65 years, 11 of 68
Table 1. Characteristics of patients.













Number 785 599 300 238 33 27
Male 406 (52%) 325 (54%) 139 (46%) 115 (48%) 14 (42%) 19 (70%)
Age $65 years 282 (36%) 278 (46%) 52 (17%) 64 (27%) 9 (27%) 7 (26%)
Medical risk factors 631 (80%) 488 (81%) 226 (75%) 167 (70%) 23 (70%) 20 (74%)
Pregnant* 4 (1%) 9 (3%) 18 (11%) 13 (11%) 0 (0%) 2 (25%)
Indigenous 70 (9%) 45 (8%) 11 (4%) 12 (5%) 0 (0%) 2 (7%)
Nursing home resident 24 (3%) 40 (7%) 3 (1%) 7 (3%) 1 (3%) 0 (0%)
ICU/HDU admission 205 (26%) 147 (25%) 80 (27%) 51 (21%) 4 (12%) 4 (15%)
Pneumonia 502 (64%) 339 (57%) 113 (38%) 74 (31%) 6 (18%) 4 (15%)
Received influenza
immunisation
424 (54%) 99 (33%) 10 (30%)
*expressed as proportion of female patients.
doi:10.1371/journal.pone.0068760.t001
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(16%) vaccinated patients and 59 of 204 (26%) unvaccinated
patients were admitted to ICU (p= 0.038).
Imputed analysis. Details of patients in which vaccine status
was not ascertained are listed in table 1. A multiple imputation
procedure was performed imputing missing vaccine status based
on age group, pregnancy, Indigenous ethnicity, presence of
chronic respiratory disease, chronic cardiac disease, current
malignancy, immunosuppression, connective tissue disease, neu-
rological disease, nursing home residence, renal disease and
influenza diagnosis. Based on an imputed set analysis and stratified
on decile of propensity score, the estimated vaccine effectiveness
was 42.7% (95% CI: 22.5, 57.7%). The estimated vaccine
effectiveness using different methods of analysis are depicted in
Figure 3.
Discussion
Over the 2010 and 2011 seasons, there was a good match
between the influenza strains in the vaccine and circulating strains
[10]. Our findings suggest that vaccination is moderately
protective against hospitalisation with confirmed influenza. The
results were similar when either simple statistical adjustment or
propensity scoring was used. In this hospitalised population,
vaccination coverage was similar to that reported in national
surveys.
The estimated vaccine effectiveness in this study is lower than
that reported against H1N1/09 influenza in 2010 [5]. This may
reflect the relative lack of genetic change in the H1N1/09 strain
since it emerged in 2009, and a poorer antigenic match with other
strains. We included the monovalent H1N1/09 vaccine in our
definition of vaccinated in 2010, as the majority of circulating
influenza was H1N1/09 strain. There are few other studies in
hospitalised patients with confirmed influenza; a Spanish group
found that none of 64 patients hospitalised with pandemic H1N1/
09 influenza were vaccinated, compared to 9 of 101 test negative
hospitalised controls [11]. A US study estimated at vaccine
effectiveness of 61%, but this was based on only 39 patients with
confirmed influenza [12]. A study from the Netherlands estimated
only a modest effect of influenza vaccine on hospitalisation with
influenza (VE 19%, 95% CI: 228%, 49%) but vaccine coverage
in this population appeared to be low [13].
Most previous studies of influenza vaccination have been
conducted in primary care. The vaccine effectiveness against
hospitalisation from influenza may be different from that against
medically presented influenza in the community for several
Figure 1. Observed vs model predicted vaccination status by decile of propensity score.
doi:10.1371/journal.pone.0068760.g001
Table 2. Factors associated with vaccination: propensity
score construction.
Odds ratio (95% CI)
Any chronic illness 0.94 (0.53, 1.66)
Age .=65 years 3.45 (1.50, 7.90)
Interaction age.= 65 years and chronic
illness
1.69 (0.66, 4.29)
Male gender 0.93 (0.67, 1.30)
Pregnancy 2.47 (0.33, 18.73)
Indigenous ethnicity 1.37 (0.74, 2.54)
Number of medical comorbidities 1.26 (0.86, 1.84)
Chronic respiratory disease 1.59 (0.96, 2.64)
Chronic cardiac disease 1.41 (0.75, 2.66)
Current malignancy 0.72 (0.33, 1.59)
Immunosuppression 1.37 (0.75, 2.50)
Connective tissue disease 1.09 (0.36, 3.30)
Chronic neurological disease 1.06 (0.54, 2.10)
Nursing home resident 2.49 (0.71, 8.68)
Chronic renal disease 0.63 (0.31, 1.26)
Current smoker 0.48 (0.31, 0.73)
doi:10.1371/journal.pone.0068760.t002
Influenza Vaccine Effectiveness
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reasons. Vaccines may be less immunogenic in the elderly, or
patients with respiratory and other chronic disease may still
require hospitalisation with minor infections. Several community-
based studies performed since 2009 have generally shown high
protective efficacy, with estimates of effectiveness of the 2010
seasonal vaccines ranging from 59%–79% [14,15] and the
monovalent H1N1/09 vaccine between 56–93%. [16–19].
There have been surprisingly few studies that have examined
the effectiveness of influenza vaccine against serious complications.
Most previous studies of influenza vaccination and hospitalisation
have examined its effectiveness against hospitalisation with
clinically diagnosed influenza and/or pneumonia, rather than
PCR confirmed influenza [20,21]. Although pneumonia is
probably a more sensitive endpoint for influenza-related illness





stratification by decile of propensity score
Unvaccinated Vaccinated
Number of patients 360 424
Age .=65 years 52 (14.4%) 230 (54.2%) 23.0% 3.9%
Female gender 179 (49.7%) 199 (46.9%) 25.0% 1.1%
Pregnant 2 (0.6%) 2 (0.5%) 0.5% 26.4%
indigenous 37 (10.3%) 33 (7.8%) 8.2% 5.5%
Any chronic illness 258 (71.7%) 373 (88.0%) 15.5% 21.6%
Chronic respiratory disease 136 (37.8%) 238 (56.1%) 24.8% 20.2%
Chronic cardiac disease 46 (12.8%) 148 (34.9%) 18.6% 25.8%
Current malignancy 23 (6.4%) 39 (9.2%) 7.3% 7.2%
Immunosuppression 86 (23.9%) 132 (31.1%) 20.4% 6.5%
Connective tissue disease 7 (1.9%) 15 (3.5%) 2.6% 1.7%
Chronic neurological disease 28 (7.8%) 54 (12.7%) 10.1% 24.6%
Nursing home resident 4 (1.1%) 20 (4.7%) 2.4% 11.3%
Chronic renal disease 37 (10.3%) 51 (12.0%) 10.9% 20.7%
Current smoker 104 (28.9%) 55 (13.0%) 16.3% 24.8%
doi:10.1371/journal.pone.0068760.t003
Figure 2. Estimated vaccine effectiveness (based on stratified analysis on propensity score) in subgroups and sensitivity analysis.
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(as not all patients are tested for influenza, and some cases of
secondary bacterial pneumonia would be PCR negative at
presentation), PCR confirmed influenza is likely to be much more
specific, as the majority of cases of pneumonia would be due to
other pathogens against which the influenza vaccine would not be
effective. Because some patients with pneumonia may have had a
preceeding undiagnosed infection with influenza and might be
PCR negative on admission, we performed a sensitivity analysis
excluding patients with pneumonia, with similar estimates.
Studies using an endpoint of confirmed influenza have generally
shown a higher effectiveness compared to those using non-specific
clinical endpoints, although studies that include serological
endpoints are thought to overestimate vaccine effectiveness [3].
In a recent systematic review of 17 randomized controlled trials
and 14 observational studies, the pooled vaccine efficacy against
confirmed influenza was estimated at 59% [3]. However, only one
of these studies examined the effectiveness of influenza vaccination
to prevent hospitalisation. [12].
We also found some evidence that vaccinated patients admitted
with influenza were not as severely unwell as unvaccinated
patients, based on a lower proportion admitted to intensive care.
Some studies have found that patients with vaccine failure had
milder illnesses [22] and were less likely to present to primary care
practitioners [23]. This may reflect attenuation of influenza disease
severity by partial protection, and appeared to be more
pronounced in the non-elderly population. However, further work
is required to confirm this finding in hospitalised patients and the
small numbers and incomplete ascertainment of vaccination
preclude further robust analysis.
The strengths of this study were that we used the highly specific
outcome measure of PCR-confirmed influenza and were able to
verify comorbidities from the medical record and/or patient
interview. However, this study had several limitations. Immuni-
sation status could not be ascertained in a substantial proportion of
cases and controls. Excluding patients where vaccination status
was not known may result in bias if the characteristics of patients
where vaccination status was not known are systematically
different to those where vaccination status was ascertained but
only if these differences are not accounted for in an adjusted
analysis. In this study, the characteristics of patients where
vaccination status was not known were similar to those included
in the analysis, which makes bias less likely.
We adjusted for several potential confounders, including age,
the presence of medical comorbidities, and pregnancy; because
Table 4. Factors associated with hospitalisation with confirmed influenza: simple multivariate analysis.
Factors Crude OR (95% CI) p Adjusted OR (95% CI) p
Female 1.28 (0.96, 1.70) 0.10
Age $65 years 0.33 (0.23, 0.47) ,0.001 0.45 (0.31, 0.67) ,0.001
Medical comorbidities 0.69 (0.49, 0.97) 0.03 0.91 (0.63, 1.31) 0.60
Influenza vaccination 0.43 (0.32, 0.59) ,0.001 0.63 (0.45, 0.88) 0.01
Pregnancy 16.29 (4.56, 58.23) ,0.001 10.36 (2.86, 37.58) ,0.001
Indigenous 0.84 (0.37, 1.90) 0.67
Resident in nursing home 0.53 (0.17, 1.66) 0.28
doi:10.1371/journal.pone.0068760.t004
Figure 3. Estimated vaccine effectiveness, by method of analysis.
doi:10.1371/journal.pone.0068760.g003
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publicly funded vaccine is available to these groups at risk of severe
influenza, this resulted in a lower adjusted estimate of vaccine
effectiveness. However, we cannot exclude the possibility of
unmeasured confounding, most notably attendance at primary
care, although the degree to which this is a confounder for
hospitalisation with influenza is uncertain. We found older age to
be protective, consistent with previous reports suggesting that this
population may have been protected by prior exposure [24]. As
many hospitals had discontinued the use of H1N1/09 specific
PCRs in favour of assays that only distinguished between influenza
A and influenza B, we were not able to provide estimates of VE
against specific subtypes in 2011. However, data from national
surveillance systems suggests that the majority of influenza A
strains in 2010 were H1N1/09 with a substantial minority due to
H3N2 subtype [10].
In the test negative study design, it is assumed that the
proportion of influenza-negative patients admitted reflects the
vaccination status of the general population at risk of hospitalisa-
tion, as influenza vaccination is not expected to have any effect on
non-influenza respiratory illnesses. We found that the proportion
of control patients $65 years who were vaccinated was 82% and
those with comorbidities was 59%. This is similar to that reported
in national surveys of vaccine coverage where 74.6% of adults
$65 years and 53.4% of people with chronic disease were
vaccinated [25]. Although we did not find the elderly and those
with comorbidities to be at risk of hospitalisation with influenza,
this is only in comparison to hospitalised influenza-negative
patients. As the decision whether to test patients for influenza
was left to the discretion of clinicians, and data are not available on
patients with influenza-like illness who were not tested, we cannot
exclude the possibility of selection bias. However, this would only
be expected to bias the result if the decision to test was correlated
with vaccination.
Both clinical trials and more recent observational data provide
strong evidence that influenza vaccination is effective in reducing
illness due to influenza [3]. In the two influenza seasons following
the emergence of the H1N1/09 influenza, we have also found that
the available influenza vaccines reduce the risk of hospitalisation in
vaccinated patients compared to unvaccinated controls. This study
supports public health policy to reduce severe influenza disease by
immunising high-risk patients with influenza vaccine.
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